Filtered By:
Therapy: Immunotherapy

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 6127 results found since Jan 2013.

Allergen ‐specific immunotherapy by recombinant Der P1 allergen‐derived peptide‐based vaccine in an allergic mouse model
ConclusionThe use of present available recombinant proteins is considered a viable, cost-effective, and long-term option for providing effective HDM allergy immunotherapy vaccines without side effects.
Source: Immunity, Inflammation and Disease - June 9, 2023 Category: Allergy & Immunology Authors: Soheila Asoudeh Moghanloo, Mohsen Forouzanfar, Mojtaba Jafarinia, Mohammad R. Fazlollahi, Gholam Ali Kardar Tags: ORIGINAL ARTICLE Source Type: research

Safe to Stop Immunotherapy at 2 Years in Stable Lung Cancer Safe to Stop Immunotherapy at 2 Years in Stable Lung Cancer
A large review has found no difference in overall survival with fixed-duration vs ongoing ICI treatment in progression-free non –small cell lung cancer.Medscape Medical News
Source: Medscape Allergy Headlines - June 6, 2023 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Cat and dog specific immunotherapy impact on quality of life and self-reported satisfaction in a real-world setting
Eur Ann Allergy Clin Immunol. 2023 Jun 6. doi: 10.23822/EurAnnACI.1764-1489.300. Online ahead of print.NO ABSTRACTPMID:37278197 | DOI:10.23822/EurAnnACI.1764-1489.300
Source: European Annals of Allergy and Clinical Immunology - June 6, 2023 Category: Allergy & Immunology Authors: M Colque-Bayona J Dominguez-Ortega M Tom ás-Pérez Source Type: research

Moving forward with allergen immunotherapy: the significance of real-world studies.
Source: Journal of Allergy and Clinical Immunology - June 3, 2023 Category: Allergy & Immunology Authors: Roy Gerth van Wijk, Paul van Daele Source Type: research

Moving forward with allergen immunotherapy: The significance of real-world studies
The efficacy of allergen immunotherapy (AIT) has been validated through numerous randomized clinical trials (RCTs). These trials have a rigid design with strict inclusion and exclusion criteria for participants, well-accepted outcome measures, standardized procedures for administering concurrent medications, and regular patient monitoring. These conditions are optimal for obtaining registration and market authorization for new AIT products. However, the study populations in RCTs may not be representative of the typical patient population in daily practice, as the latter group may have more diverse demographic and clinical characteristics.
Source: Journal of Allergy and Clinical Immunology - June 3, 2023 Category: Allergy & Immunology Authors: Roy Gerth van Wijk, Paul van Daele Tags: Editorial Source Type: research

Thyroid Dysfunction Mild With Cancer Immunotherapy Thyroid Dysfunction Mild With Cancer Immunotherapy
In a real-world study, the prevalence of immune checkpoint inhibitor –associated thyroid dysfunction was greater than 50%, but cases were mild and were even linked to better survival.Medscape Medical News
Source: Medscape Allergy Headlines - June 2, 2023 Category: Allergy & Immunology Tags: Diabetes & Endocrinology News Source Type: news

Recurrence patterns among patients with sinonasal mucosal melanoma: a multi ‐institutional study
ConclusionSNMM is associated with a high recurrence rate and poor survival. Primary treatment of the neck was not associated with reduced recurrence, and immunotherapy for treatment of distant recurrence was associated with increased 12-month PRS.This article is protected by copyright. All rights reserved
Source: International Forum of Allergy and Rhinology - June 2, 2023 Category: Allergy & Immunology Authors: Vivek C. Pandrangi, Jess C. Mace, Arash Abiri, Nithin D. Adappa, Daniel M. Beswick, Eugene H. Chang, Jacob G. Eide, Nicholas Fung, Michelle Hong, Brian J. Johnson, Michael A. Kohanski, Rijul S. Kshirsagar, Edward C. Kuan, Christopher H. Le, Tags: ORIGINAL ARTICLE Source Type: research

Practice-Changing Data on Low ER+ Breast Tumors? Practice-Changing Data on Low ER+ Breast Tumors?
The immune landscape for low and intermediate estrogen receptor-positive breast tumors appears to mimic that for triple-negative tumors, suggesting a potential role for immunotherapy.Medscape Medical News
Source: Medscape Allergy Headlines - June 1, 2023 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Risk Factors for Recalcitrant Chronic Rhinosinusitis in Non-Solid and Solid Transplant Recipients
CONCLUSION: Risk of ESS was greater in the solid transplant recipients compared to those who received non-solid organ transplant.PMID:37262001 | DOI:10.1177/19458924231177855
Source: American Journal of Rhinology and Allergy - June 1, 2023 Category: ENT & OMF Authors: Estephania Candelo Ashley Darakjian Karol Avila-Castano Angela Donaldson Source Type: research

EE183 Cost-Effectiveness Model for PTAH Oral Immunotherapy in Peanut Allergy Using Two-Year Extension Trial Data
The Institute for Clinical and Economic Review (ICER) published a report of the cost-effectiveness of peanut allergy immunotherapy treatment AR-101 (Peanut (Arachis hypogaea) Allergen Powder-dnfp, “PTAH”) compared to avoidance alone in 2019. PTAH was approved by the FDA in 2020 and two-year extension trial data is now available. Our objective was to replicate and update the previously developed ICER model for PTAH to include extension trial data and updates to drug costs.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: V. Dayer, R.N. Hansen, J.J. Carlson Source Type: research

Food Allergy: Emerging Therapies
Abstract Purpose of Review The purpose of this review is to discuss the current and emerging treatment options of food allergy.Recent FindingsThe mainstay of treatment for food allergy was traditionally avoidance and/or symptomatic antihistamine and adrenaline treatment depending on severity of symptoms. In the past two decades, allergen-specific immunotherapy and biologic therapies have emerged as treatment options to increase the threshold of reactivity to specific food allergens. Allergen-specific approaches include oral, sublingual, subcutaneous, and epicutaneous immunotherapy as well as DNA vaccines. Monoclonal an...
Source: Current Treatment Options in Allergy - May 31, 2023 Category: Allergy & Immunology Source Type: research